In Vitro Exposure of Cultured Porcine Choroid Plexus Epithelial Cells to Immunosuppressant, Anti-Inflammatory, and Psychoactive Drugs

Cell Transplantation

Brief Communication

Jebecka Hudak¹  Patricia Schneider¹  Briannan Bintz¹  Christopher G. Thanos¹  Dwaine F. Emerich¹ 

[1] LCT BioPharma, Inc., Providence, RI, USA;

关键词: Choroid plexus;    Xenotransplant;    Vascular endothelial growth factor (VEGF);    Encapsulation;   

DOI  :  10.3727/000000007783464867

 received in 2006-07-24, accepted in 2006-08-07,  发布年份 2007

来源: Sage Journals

【 摘 要 】

Delivery of neurotrophic molecules to the CNS is a potential treatment for preventing the neuronal loss in neurological disorders such as Huntington's disease (HD). Choroid plexus (CP) epithelial cell transplants secrete several neurotrophic factors and are neuroprotective in rat and monkey animal models of HD. HD patients receiving CP transplants would likely receive a course of immunosuppressant/anti-inflammatory treatment postsurgery and would remain on psychoactive medications to treat their motor, psychiatric, and emotional symptoms. Therefore, we examined whether CP epithelial cells are impacted by incubation with cyclosporine A (CsA), dexmethasone, haloperidol, fluoxetine, and carbamezapine. In each case, DNA was quantified to determine cell number, a formazen dye-based assay was used to quantify cell metabolism, and vascular endothelial growth factor (VEGF) levels were measured as a marker of protein secretion. Except for the highest dose of fluoxetine, none of the drugs tested exerted any detrimental effect on cell number. Incubation with CsA or dexamethasone did not have any consistent significant effect on VEGF secretion or cell metabolism. Carbamazepine was without effect while only the highest dose of haloperidol tested modestly lowered cell metabolism. VEGF secretion and cell metabolism was not measurable from CP cells exposed to 100 μM fluoxetine. These data continue to support the potential use of CP transplants in HD.

【 授权许可】

Unknown   
© 2007 Cognizant Comm. Corp.